Attempts at predicting drug-drug interactions perpetrated by paroxetine from in vitro data have utilized reversible enzyme inhibition models and have been unsuccessful to date, grossly underpredicting interaction magnitude. Recent data have provided evidence for mechanismbased inactivation of CYP2D6 by paroxetine. We have predicted the pharmacokinetic predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used. In summary, the scaling model for mechanism-based inactivation successfully predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro data.
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INTRODUCTION
Paroxetine (Paxil ® ) is a widely used selective serotonin reuptake inhibitor (SSRI) antidepressant that is indicated for the treatment of major depressive disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder and post-traumatic stress disorder.
Paroxetine is an established perpetrator of drug-drug interactions (DDI's) when coadministered with agents whose clearance is largely dependent on the activity of cytochrome P450 2D6 (CYP2D6). Examples of characterized clinical interactions with paroxetine include its effects on the kinetics of desipramine (Brøsen et al., 1993; Alderman et al., 1997) , perphenazine (Özdemir et al., 1997) , metoprolol (Hemeryck et al., 2000) , risperidone (Spina et al., 2001 ) and atomoxetine (Belle et al., 2002) where the clearance of the victim drugs is impaired by 5-8-fold.
In addition, paroxetine displays nonlinear accumulation kinetics with steady-state exposures exceeding projections from single dose kinetics by ~5-fold in CYP2D6 extensive metabolizers but not in CYP2D6 poor metabolizers (Kaye et al., 1989; Sindrup et al., 1992) . This has been attributed to metabolic saturation following multiple dosing (Sindrup et al., 1992) although supporting evidence at the enzyme kinetic level is lacking. In vitro studies have reproducibly demonstrated potent inhibition of human liver microsomal CYP2D6 activity via an apparent competitive mechanism (von Moltke et al., 1995; Otton et al., 1996; Hemeryck et al., 2001 ).
However, attempts at in vitro-in vivo extrapolation (IVIVE) of interaction magnitude under the assumption of reversible inhibition have been largely unsuccessful, even when nonspecific microsomal binding in vitro was considered (Hemeryck et al., 2001) or empirical approaches such as application of total plasma or even total intrahepatic concentrations of paroxetine were used in the predictions (von Moltke et al., 1995; Hemeryck et al., 2000) . This article has not been copyedited and formatted. The final version may differ from this version. Recent data have provided evidence for mechanism-based inactivation (MBI) of CYP2D6 by paroxetine (Bertelsen et al., 2003) . Paroxetine produced a concentration and timedependent inhibition of human liver microsomal CYP2D6 activity in vitro, as measured by dextromethorphan O-demethylation rate. Kinetic analysis revealed that paroxetine produced a metabolism-dependent rapid loss of activity of the enzyme with a half-life of inactivation of 4 minutes (k inact 0.17 min -1 ), and biochemical evidence for metabolite intermediate complexation via a carbene-heme complex with CYP2D6 (Bertelsen et al., 2003) .
Whereas in vitro-in vivo scaling approaches for reversible inhibition of CYP enzymes have been extensively described over the last decade and applied in the prediction of drug-drug interactions, mathematical models for scaling interactions resulting from mechanism-based inhibition have only recently been described, with relatively fewer reported examples illustrating their predictive utility. Of notable mention are the reasonably successful predictions of the interactions perpetrated by fluoxetine, diltiazem, clarithromycin, verapamil and the HIV protease inhibitors with CYP3A4 substrates using a mathematical model of mechanism-based inhibition developed by Hall and colleagues (Mayhew et al., 2000; Wang et al., 2004; Ernest II et al., 2005) . In vitro-In vivo extrapolations using this model require a formal kinetic analysis of inactivation by the perpetrator agent to determine the potency of inactivation (K I ) and maximal inactivation rate (k inact ). An estimate of the enzyme-available concentration of the inhibitor is necessary (as for scaling models for reversible inhibition). In addition, an estimate of the in vivo degradation rate (k degrad ) of the enzyme in humans is needed.
In this report, we describe the application of the scaling model for mechanism-based inhibition in predicting the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro data. Specifically, we describe predictions of (a). the nonlinear 
In Equation 1, CL int,I and CL int,control are the intrinsic clearance of the metabolic pathway of the victim drug in the presence and absence of the mechanism-based inactivator (concentration I).
The inactivation rate constant k inact (maximal inactivation rate at saturating concentration of the inactivator) and the potency K I (inactivator concentration at which half-maximal inactivation rate is achieved), which are typically measured in vitro, are the primary kinetic parameters describing the MBI process, and k degrad represents the first-order rate constant for degradation (turnover) of the enzyme in vivo. If the victim drug is dosed orally, completely absorbed, and cleared entirely by hepatic metabolism by the inactivated enzyme, the apparent oral clearance (CL po ) should equal CL int , and fractional decrement in oral clearance (FDCL) can thus be described as:
In the application of this model to scaling DDI's perpetrated by paroxetine via MBI of CYP2D6, it was assumed that non-CYP2D6 clearance mechanisms of the victim drugs of interest (desipramine, risperidone, perphenazine, atomoxetine, (S)-metoprolol and (R)-metoprolol) were unaffected by paroxetine treatment. Thus, the fractional decrement of total oral clearance (FDCL tot ) was calculated as follows, where f 2D6 represents the fractional contribution of CYP2D6 to the overall oral clearance of the specific victim drug:
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The magnitude of the DDI (fold-increase in victim drug AUC) was predicted as follows:
The above described approach was also used to assess the extent of nonlinear accumulation of paroxetine following multiple dose-administration, with the only conceptual difference being that paroxetine is considered as both the perpetrator and victim drug in the analysis (i.e. autoinactivation).
Estimation of Model Inputs.
As prerequisites to the IVIVE exercise, the following model inputs were estimated: k inact , K I , k degrad , I, and f 2D6 .
In vitro kinetic analysis of MBI of CYP2D6 by paroxetine has been previously described (Bertelsen et al., 2003) and the following kinetic parameters were reported: k inact of 0.17 min -1 and K I of 4.85 µM. A human liver microsomal protein concentration of 2.5 mg/mL was used in the preincubation with paroxetine in these studies of time and concentration-dependent effects on CYP2D6 activity. The estimated unbound fraction of paroxetine at the microsomal protein concentration used in the kinetic MBI studies is 0.065, extrapolated from the results of previously described human liver microsomal binding experiments (Hemeryck et al., 2001 ).
Thus, the unbound K I for paroxetine inactivation of CYP2D6 was determined as 0.315 µM.
Both "total" and "unbound" K I estimates (4.85 µM and 0.315 µM, respectively) were explored as inputs for scaling to assess the utility of nonspecific binding considerations in the estimation of inhibitor potency.
An indirect approach was used to determine k degrad for CYP2D6 from the time course of return of CYP2D6 activity (measured as the dextromethorphan/dextrorphan urinary metabolic The inhibitor concentration (I) was estimated as the unbound steady-state average concentration of paroxetine from total systemic exposures that were either measured in the specific drug-drug interaction studies or reported in previously published literature on the clinical pharmacokinetics of paroxetine (Kaye et al., 1989) , and an unbound fraction (f u ) of 0.05 in human plasma (Kaye et al., 1989) . Other estimates of inhibitor concentration including the total systemic concentration and the steady-state maximum unbound concentration at the inlet to the liver (estimated using Equation 5 which includes the steady-state systemic paroxetine C max and an additive portal venous "absorption" component as described by Kanamitsu et al., 2000) were also evaluated as alternative inputs to the model. et al., 1989 ) and a hepatic blood flow (Q h ) of 1500 mL/min was assumed (Davies and Morris, 1993) .
The fractional contribution of CYP2D6 to the overall oral clearance of each victim drug (f 2D6 ) was estimated from its clinical pharmacokinetics in CYP2D6 extensive metabolizers and poor metabolizers (Table 1) (Davies and Morris, 1993) , the impact of autoinactivation on the systemic clearance and oral bioavailability of paroxetine at steady-state were estimated from the model-predicted fractional decrement in apparent oral clearance (intrinsic clearance), in the context of a well-stirred pharmacokinetic model (Wilkinson and Shand, 1975) . Assuming that autoinactivation does not alter volume of distribution (but would alter the apparent volume of distribution (V/F) due to alteration of the bioavailability F) or absorption kinetics, and that changes in systemic clearance will be reflected as changes in 117% (range: 90%-140%) when the estimated unbound maximal concentration at the inlet to the liver was used, and was 127% (range: 97%-140%) when the total systemic concentration was used.
The performance of the scaling model is illustrated in Figure 2 for the interaction of paroxetine with desipramine (Alderman et al., 1997) . For purposes of this exercise, the steadystate pharmacokinetic profile of desipramine (50 Table   2 ), in the context of a well-stirred pharmacokinetic model (Wilkinson and Shand, 1975) .
Assuming that the interaction does not alter volume of distribution (but would alter the apparent volume of distribution (V/F) due to alteration of F) or absorption kinetics, and that changes in systemic clearance will be reflected as changes in desipramine's elimination half-life, the following pharmacokinetic parameters for desipramine post-CYP2D6 inactivation were derived: apparent volume of distribution (V/F) 1122 L; and elimination rate constant (k el ) 0.0122 hr -1 .
The corresponding superpositioned steady-state profile is represented in Figure 2 A key assumption of the scaling model used here is that enzyme inactivation is the sole mechanism of these DDIs, since the reversible component of CYP2D6 inhibition by paroxetine is not considered. Further, it is also assumed that the effect of paroxetine is substrateindependent. This is based on the assumption that the MBI completely prevents substrate binding in a productive orientation at the enzyme active site(s), such that metabolic capacity towards all substrates would be equally affected. Atypical kinetics of dextromethorphan metabolism by CYP2D6 have been described (Yu et al., 2001) , suggesting that multiple binding orientations are possible. Thus the theoretical possibility remains that the assumption of substrate independence of K I and k inact of mechanism-based inactivation of CYP2D6 by paroxetine may not be true, if the MBI results in an orientation-specific (and hence substratedependent) loss of substrate binding at the enzyme active site. Nevertheless, paroxetine reproducibly impairs the clearance of structurally diverse CYP2D6 substrates, which would suggest that the likelihood of paroxetine producing substrate-specific CYP2D6 inhibition is small and of limited clinical relevance.
The lack of information on the in vivo degradation rates of many human drug metabolizing CYPs represents a significant limitation that increases the uncertainty in risk (Emery et al., 1999) . Thus, the estimated CYP2D6 halflife of 51 hours is in excellent agreement with the degradation half-life estimated for another human CYP isoform within the same family, using a similar indirect approach. When information on enzyme half-life is not available, compound-specific analysis of the sensitivity of the IVIVE model to k degrad represents a useful approach to estimating the level of confidence in the predicted DDI magnitude. The same is applicable when there is uncertainty in the estimated enzyme-available inhibitor levels due to possible active hepatic uptake (von Moltke et al., 1998) or transient high concentrations during first-pass through the liver (Ito et al., 1998; Kanamitsu et al., 2000) .
In the current retrospective analysis, the possibility of concentrative hepatic uptake of paroxetine has not been considered due to the lack of data on the extent of hepatocellular uptake of paroxetine, or identified biochemical mechanisms of active hepatic uptake transport of this drug. Paroxetine displays extensive hepatic distribution, with a liver/plasma total concentration ratio of ~26 (von Moltke et al., 1995) . However, it is unknown whether this extent of distribution is significantly in excess of that expected from the relative extents of plasma and This article has not been copyedited and formatted. The final version may differ from this version. 
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